Given consistent CDADC1 expression across cancer types but with higher levels in leukemia (SI Appendix, Figs. S2D and S5 B and C), we compared decitabine sensitivity of WT and CDADC1-deficient cell lines from human T-cell acute lymphoblastic leukemia (Molt-4 and Jurkat), acute myeloid leukemia (THP-1), and chronic myeloid leukemia (K562). This evidence concerns the gene CDADC1 and chronic myelogenous leukemia, BCR-ABL1 positive.